| __timestamp | CymaBay Therapeutics, Inc. | Wave Life Sciences Ltd. |
|---|---|---|
| Wednesday, January 1, 2014 | 8185000 | 2999000 |
| Thursday, January 1, 2015 | 8871000 | 10393000 |
| Friday, January 1, 2016 | 9645000 | 15994000 |
| Sunday, January 1, 2017 | 12387000 | 26975000 |
| Monday, January 1, 2018 | 14381000 | 39509000 |
| Tuesday, January 1, 2019 | 19238000 | 48869000 |
| Wednesday, January 1, 2020 | 17425000 | 42510000 |
| Friday, January 1, 2021 | 23040000 | 46105000 |
| Saturday, January 1, 2022 | 25116000 | 50513000 |
| Sunday, January 1, 2023 | 51953000 | 51292000 |
Data in motion
In the dynamic world of biotechnology, understanding financial trends is crucial for investors and stakeholders. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent biotech companies: CymaBay Therapeutics, Inc. and Wave Life Sciences Ltd., from 2014 to 2023. Over this period, Wave Life Sciences consistently outpaced CymaBay in SG&A spending, peaking at approximately $51 million in 2022, a 70% increase from 2014. Meanwhile, CymaBay's expenses surged dramatically by over 500% from 2014 to 2023, reaching a high of $52 million. This significant rise in CymaBay's expenses in 2023 suggests a strategic shift or expansion. Such financial insights are pivotal for understanding each company's operational strategies and market positioning. Investors should consider these trends when evaluating potential growth and risk factors in the biotech sector.
Selling, General, and Administrative Costs: Sanofi vs CymaBay Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Alnylam Pharmaceuticals, Inc. and Wave Life Sciences Ltd.
BeiGene, Ltd. or Wave Life Sciences Ltd.: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Genmab A/S and Wave Life Sciences Ltd.
Neurocrine Biosciences, Inc. and Wave Life Sciences Ltd.: SG&A Spending Patterns Compared
Incyte Corporation vs Wave Life Sciences Ltd.: SG&A Expense Trends
Breaking Down SG&A Expenses: Amneal Pharmaceuticals, Inc. vs CymaBay Therapeutics, Inc.
Comparing SG&A Expenses: CymaBay Therapeutics, Inc. vs Xenon Pharmaceuticals Inc. Trends and Insights
Who Optimizes SG&A Costs Better? CymaBay Therapeutics, Inc. or ImmunityBio, Inc.
Cost Management Insights: SG&A Expenses for CymaBay Therapeutics, Inc. and MannKind Corporation
Who Optimizes SG&A Costs Better? CymaBay Therapeutics, Inc. or Evotec SE
Breaking Down SG&A Expenses: Agios Pharmaceuticals, Inc. vs Wave Life Sciences Ltd.